High Purity New England Launches Third Facility
High Purity New England has launched its third facility, focused on single-use assemblies.
High Purity New England (HPNE), a supplier of single-use solutions for the biopharmaceutical industry, has launched its third new state-of-the-art facility. The facility is designed to accelerate HPNE’s ability to provide its customers with single-use assemblies and significantly increase the company’s manufacturing capacity.
The facility represents a $10 million investment, sized at approximately 80,000 square feet. It will serve as the company’s Specialty Manufacturing and Distribution Center. The facility features an extensive laboratory with four suites, an auditorium, a mock cleanroom for onboarding employees to practice gowning and S.O.P training, and two floors of warehouse space for materials and finished goods. It will also house additional office space and community space used for industry and local organizations, such as the Boys & Girls’ Club of RI and RI Bio.
HPNE supplies a range of products, including custom single-use assemblies, pumps, mixers, and other single-use solutions. The company’s total square footage is now greater than 130,000 square feet with the addition of the new facility, increasing their abilities to provide products to its customers.
Source: HPNE
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
